title: High daily fraction dose external radiotherapy for T1 glottic carcinoma: treatment results and prognostic factors.
abstract: BACKGROUND
  The purpose of this study was to investigate the prognostic factors and treatment results of T1N0M0 glottic laryngeal carcinoma irradiated with 2.3 Gray (Gy) per fraction.
  
  
  METHODS
  A total of 183 patients with glottic carcinoma treated between June 1998 and January 2007 were retrospectively evaluated. Of the 183 patients, 163 patients (89%) had T1a and 20 patients (11%) had T1b disease. All patients received 2.3 Gy per fraction to a median total dose of 64.4 Gy.
  
  
  RESULTS
  The median follow-up was 63 months. The 5-year overall survival (OS), local control, and cancer-specific survival rates were 89%, 81%, and 90%, respectively. Multivariate analysis showed overall treatment time and age to be significant prognostic factors for local control and OS. We observed no grade IV or grade V acute toxicity. Trachea-esophageal fistula as late toxicity was observed in only 1 patient.
  
  
  CONCLUSIONS
  High daily fraction scheme seems to be a feasible schedule for early glottic carcinomas.
authors: Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
authors: Melis
authors: M
authors: Gultekin
authors: Enis
authors: E
authors: Ozyar
authors: Mustafa
authors: M
authors: Cengiz
authors: Gokhan
authors: G
authors: Ozyigit
authors: Mutlu
authors: M
authors: Hayran
authors: Sefik
authors: S
authors: Hosal
authors: Fadil
authors: F
authors: Akyol
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D005931:Glottis / Q000473:pathology*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome